Skip to main content
All Posts By

cece

cancer treatment reviews
Immunotherapy in non-small cell lung cancer harbouring driver mutations ResearchTreatments

Immunotherapy in non-small cell lung cancer harbouring driver mutations

*May 2021* The advent of molecular targeted therapies and the more recent introduction of immune checkpoint inhibitors (ICIs) have altered and improved the therapeutic landscape of non-small cell lung cancer (NSCLC). ICIs confer a durable response in a subset of patients; however, their therapeutic role in oncogene-driven NSCLC remains unclear,…
cece
June 21, 2021
JTO Clinical and Research Reports
Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib ResearchTreatments

Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib

*April 2021* MET amplification is a frequently observed mechanism of resistance to osimertinib, and coinhibition strategy of MET and EGFR revealed promising results in recent clinical trials. Nevertheless, acquired resistance mechanisms to combined EGFR and MET inhibition are poorly understood. In this study, we investigated the mechanisms of acquired resistance…
cece
June 21, 2021
Targeted Oncology
Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC ResearchTreatments

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC

*May 2021* The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor mutation (EFGR) mutation after progression on an EGFR tyrosine kinase inhibitor (TKI), according to results from a phase 1B/2 study…
cece
June 21, 2021
FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer ResearchTreatments

FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

*May 2021* The U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.)…
cece
June 21, 2021
Ivy Elkins
Still Living With Uncertainty Coping With Cancer

Still Living With Uncertainty

*May 2021*  from Lungcancer.net, written by Ivy  Elkins This past February 13th marked one year since having an upper right lobectomy that resulted in me reaching NED (No Evidence of Disease). Fortunately, I am still considered NED and hope that this status will last a long, long time. Oncologist visits…
cece
June 21, 2021
lungevity
LUNGevity’s HOPE Summit: Ivy Elkin’s Journey to Research Advocacy AdvocacyStories

LUNGevity’s HOPE Summit: Ivy Elkin’s Journey to Research Advocacy

*May 2021* EGFR Resister co-founder Ivy Elkins  presented with Dr. Upal Basu Roy, Executive Director of LUNGevity, on “Understanding the Science of Lung Cancer and Research Advocacy” at the 2021 Hope Summit on Saturday, May 22. Her portion of the presentation centered on the importance of patient-driven research and her…
cece
June 21, 2021
OncLive
FDA Grants Priority Review to Mobocertinib for Advanced EGFR Exon 20–Mutant NSCLC ResearchTreatments

FDA Grants Priority Review to Mobocertinib for Advanced EGFR Exon 20–Mutant NSCLC

*April 2021* The FDA has granted a priority review designation to a new drug application (NDA) for mobocertinib (TAK-788) for the treatment of adult patients with EGFR exon 20 insertion mutation–positive metastatic non–small cell lung cancer (NSCLC), as detected via an FDA-approved assay, who have received previous platinum-based chemotherapy.1 The designation is…
cece
June 21, 2021